Ramakrishna Shabaraya

The present work is aimed at Design and development of medicated lollipop containing Albendazole. One of the major health problems faced by hundreds of millions of school-age children is infection by helminths, more commonly known as worms. Albendazole is used as abroad-spectrum anthelmintic. The conventional dosage forms like tablets, capsules, syrups etc are inconvenient for paediatric, geriatric, bedridden patients because of difficult to swallow tablets and capsules or unpleasant taste of drug. As a result, the demand for developing new technologies has been increasing day by day. Lollipops are defined as the flavoured medicated dosage forms intended to be sucked and held in the mouth or pharynx containing one or more medicaments usually in the sweetened base.  Medicated lollipop is designed to improve patient compliance and increase oral retention time. The lollipops were prepared by heating and congealing method using hydroxypropylmethylcelluloseK4M as polymer. Drug-excipient compatibility study was carried out using FTIR. All the formulations were subjected to various physicochemical evaluations like weight variation, hardness, drug content, friability etc. The in-vitro dissolution study of F3 was carried out by two method a) Paddle method b) flow through cell method .The in-vitro permeation  study of F3 was found to be 72.2% at 30 min. Stability study was carried out as per ICH-Guidelines (Q1A) at 25±2oC/60±5% RH and 40±2oC/75±5% RH . From the present study it can be concluded that addition of hydrophilic polymers yield good result to prolong oral retention time of lollipop.

Development of amphiphilic drug-lipid complexes is a potential approach for improving delivery of the drugs by increasing solubility, release profile and oral bioavailability. Rutin, a polyphenolic flavonoid, shows several biological effects like capillary protectant, anti-oxidant, anti-inflammatory, anti-aging, cardio-protective, anti-thrombotic and neuroprotective, but its use is limited due to its low aqueous solubility. To overcome this limitation, phospholipid complex of Rutin was developed to improve its aqueous solubility for better absorption through the gastrointestinal tract and this might result in improved bioavailability. The Rutin phytosomes prepared by solvent evaporation method using different ratios of Rutin and Soybean phosphatidylcholine (1:1, 1:2 and 1:3) was evaluated for percentage yield, compatibility studies by infra-red spectroscopy, particle size, poly dispersity index, zeta potential, drug content and were found to be within the acceptable range. Surface morphology by scanning electron microscopy, solubility studies, in-vitro drug release and stability studies also were carried out. The phospholipid complex of Rutin was found to be fluffy and porous with rough surface. The water solubility of Rutin was improved from 0.058mg/ml to 0.475 mg/ml in the prepared Phytosomes. The in-vitro drug release studies showed that there is no drug release from pure drug and F1 formulation up to 120min in acidic buffer pH 1.2; while in phosphate buffer pH 7.4 showed releases about 49.3% and 92.85% respectively, which indicates the significant enhancement of dissolution of Rutin phytosomes compared to pure drug. Stability studies suggested that the formulations were stable. In this study, Phytosomes could be successfully tailored for Rutin with improved dissolution characteristics which is promising for lowering the influence of exogenous factors and increasing drug delivery.

Fast dissolving tablets are the tablet which dissolves rapidly and shows higher bioavailability than conventional tablets. The concept of formulating Fast dissolving tablets of Famotidine (H2 –receptor antagonist) offer suitable and practical approach in serving the desired objective of faster disintegration and dissolution characteristic with increase bioavailability and to know the effects of two synthetic superdisintegrant (Croscarmellose sodium and Sodium starch glycolate). In the present work two methods of solid dispersion were compared for improving the bioavailability i.e. Solvent Evaporation and Fusion method with PVP K30 as a carrier to increase the solubility of the drug. Comparison between these two synthetic superdisintegrant was done by taking different ratios and in combination. Three different combination of these superdisintegrant shows synergistic effect when it is compared to individual. Prepared tablets were subjected to different evaluation parameters such as hardness (2.84±0.15 kg/cm2 to 3.01±0.20 kg/cm2), friability (not more than 0.680±0.0173), weight variation (197.6±1.42 mg to 202.6±1.90 mg), drug content uniformity (97.84±0.35 to 100.23±0.71%), in vitro disintegration time (21.0±0.81 sec to 108.33±0.47 sec), wetting time (29.33±0.47 to 113.33±1.24 sec), in vitro dissolution studies and stability studies are carried out by using the best formulation. From all the formulations prepared and tested, F9 was found to the best formulation.

Medicated chewing gum (MCG) is a drug delivery system that consists of an active ingredient incorporated into a chewing gum and released by the mechanical action of chewing. The first Medicated chewing gum product.‘ Aspergum’, which contained acetyl salicylic acid for headaches, was launched in 1928. Medicated chewing gum is a good vehicle for administering active ingredients in pharmaceuticals and nutraceuticals. It offers a highly convenient, patient-compliant way of dosing medications, particularly for people with swallowing difficulties such as children and the elderly. It is also an ideal dosage form for drugs that help cure or relieve oral diseases, including toothache, periodontal disease, bacterial and fungal infections, and aphthous and dental stomatitis. Medicated chewing gum containing chlorhexidine is used to treat inflammatory conditions such as gingivitis. Using the medicated chewing gum formulation, the revitalization of old products and the reformulation of new patented products will differentiate them from upcoming generics competition. Thus, the potential of Medicated chewing gum for direct systemic delivery with higher patient compliance, its fast onset of action and the opportunity for product-line extension make it a likely drug delivery system. Keywords- Medicated chewing gum (MCG), periodontal disease, gingivitis, patient compliance